Apogee Clinical Research — research payments reported

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$293,521	79
2024	Research	$76,078	14
2023	Research	$20,139	2

Breakdown

Who paid Research payments · program years 2023–2025

Alnylam Pharmaceuticals Inc. $146,242 73 payments
Boehringer Ingelheim International GmbH $82,589 12 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $80,124 1 payment
Boehringer Ingelheim Pharmaceuticals, Inc. $56,169 6 payments
Biogen, Inc. $24,276 2 payments
Pfizer Inc. $339 1 payment

Studies the money was for Research payments · program years 2023–2025

Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) $146,242 73 payments
Phase III Renal Outcomes $94,374 2 payments
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease $68,339 11 payments
PoCP study in FSGS $31,177 3 payments
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD $24,992 3 payments
A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON (FALCON) $21,162 1 payment
An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) (EAGLE) $3,114 1 payment
A Phase 1 Openlabel Nonrandomized Study to Investigate the Safety and PK Following Multiple Oral Doses of Pf07321332 Nirmatrelvirritonavir in Adult Participants With Covid19 and Severe Renal Impairment Either on Hemodialysis Or Not on Hemodialysis $339 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.